Patents Assigned to Centers For Disease Control and Prevention
  • Publication number: 20220187243
    Abstract: The present application proposes a method for detecting an okadaic acid based on a near-infrared photoelectric composite material, which includes the following steps: synthesizing NaYF4: Yb, Tm up-conversion nanoparticles (UCNPs) and a semiconductor material flower-like tungsten oxide (WO3) by a simple high-temperature solvothermal method; coupling the UCNPs with an okadaic acid monoclonal antibody through a classic amidation reaction to construct a competitive near-infrared photoelectrochemical immunosorbent assay (cNIR-PECIA) for okadaic acid detection. In addition, the present application employs a screen-printed carbon electrode (SPE) as the working electrode, and thus only requires a small amount of electrolytes, which is low-cost and maintenance-free.
    Type: Application
    Filed: October 21, 2021
    Publication date: June 16, 2022
    Applicants: JiMei University, Xiamen Center for Disease Control and Prevention
    Inventors: Xiaomei CHEN, Chenyan ZHENG, Mingming YIN, Bingyuan SU, Jie WEI
  • Publication number: 20220142933
    Abstract: The present application provides a method for preparing a probiotic-loaded microcapsule including: (1) dissolving sodium alginate in a solvent to obtain a sodium alginate solution; (2) evenly mixing a probiotic with the sodium alginate solution obtained in step (1) to obtain a probiotic suspension; and (3) spraying the probiotic suspension obtained in step (2) into a salt solution, stirring and curing, to obtain the probiotic-loaded microcapsule. The microcapsule is prepared by a spraying method in conjunction with an ion curing method by using sodium alginate as the wall material of the microcapsule, so that the prepared microcapsule has a good spherical shape, a small particle size, good dispersibility and high pH sensitivity, forms a denser surface under an acidic condition to effectively protect probiotics, and can meet requirements for subsequent in vivo animal evaluations.
    Type: Application
    Filed: August 18, 2020
    Publication date: May 12, 2022
    Applicants: National Institute for Nutrition and Health Chinese Center for Disease Control and Prevention, Institute of Process Engineering, Chinese Academy of Sciences
    Inventors: Gangqiang Ding, Junsheng Huo, Lianyan Wang, Jian Huang, Guifeng Zhang, Yanbin Tang, Ke Cao, Yingbin Cui, Zheng Cao
  • Patent number: 11291714
    Abstract: The present invention relates to a recombinant antigen derived from Zika virus E protein and use thereof. Specifically, the present invention provides a polynucleotide encoding Zika virus E protein domain III alone or repeatedly three times, a recombinant plasmid vector comprising the polynucleotide, and a DNA vaccine composition that may induce an immune response to Zika virus by expressing a Zika virus antigen protein effectively. In addition, the present invention provides a neutralizing antibody against Zika virus obtained using the polynucleotide and a method for preparing the neutralizing antibody.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: April 5, 2022
    Assignee: Korea Center for Disease Control and Prevention
    Inventors: You-Jin Kim, Hyun Ju In, HeeJi Lim, Sun-Dong Jang, Jung-Sik Yoo, Gyung Tae Chung
  • Patent number: 11160859
    Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: November 2, 2021
    Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., CORNELL RESEARCH FOUNDATION, INC., THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION
    Inventors: Patti Cynthia Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox, William L. Castleman
  • Patent number: 11137377
    Abstract: A dispersive solid-phase extraction material, a preparation method therefor and an application thereof. The method comprises: weighing humic acid and washing it using water under ultrasonic bath, centrifuging to obtain a solid precipitate; resuspending the solid precipitate in acetone, heating and evaporating until the acetone has evaporated completely to then obtain a residue; taking and placing the residue in a Soxhlet extractor, and adding a cleaning solution; cleaning by heating and refluxing until the refluxed liquid is clear and colorless, and then heating is stopped; taking out the cleaned material; drying the material at 100° C. for 1.5-2.5 h, cooling for 0.5-1 h, and sieving through a 120 mesh sieve; collecting the material under the sieve to obtain the dispersive solid-phase extraction material. The dispersive solid-phase extraction material can simultaneously extract and purify aflatoxins in edible oils for their detection.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: October 5, 2021
    Assignee: GUANGXI ZHUANG AUTONOMOUS REGION CENTER FOR DISEASE CONTROL AND PREVENTION
    Inventors: Yang Tang, Yanhua Liao, Ping Liu, Ningsheng Lei, Chuan Liang
  • Patent number: 10934345
    Abstract: Broadly neutralizing antibodies against HIV-1 which specifically bind to gp120 of HIV-1, a method of preparing such antibodies and the use thereof are provided.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: March 2, 2021
    Assignees: NATIONAL CENTER FOR AIDS/STD CONTROL AND PREVENTION, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Yiming Shao, Jiang Zhu, Yuxing Li, Ian A. Wilson, Leopold Kong, Bin Ju, Linling He, Li Ren, Yajing Chen, Jiandong Liu
  • Patent number: 10793902
    Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase, protease, or integrase of HIV as disclosed herein. Thus, provided in an oligonucleotide comprising any one of the nucleotide sequences set forth in SEQ ID NOS: 1-89, 96-122, and 124-141. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, 96-122, and 124-141. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCT reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV simultaneously or sequentially. Mutations in the reverse transcriptase, protease, or integrase of HIV can be detected using the methods described herein.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: October 6, 2020
    Assignee: The Government of the United States of America, as Represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Jeffrey A. Johnson, Walid M. Heneine, Jonathan T. Lipscomb
  • Patent number: 10782308
    Abstract: Methods, kits and devices for detecting antineoplastic drug contamination of a surface are provided according to aspects of the present invention. According to aspects of the invention, methods for detecting antineoplastic drug contamination of a surface include providing a wetting solution compatible with the antineoplastic drug and formulated to promote release of the drug from the surface to be assayed; providing a solid matrix for reversible absorption of the antineoplastic drug; contacting the solid matrix with the wetting solution, generating an assay matrix; contacting the assay matrix and the surface, generating a surface sample; contacting the surface sample with a volume of wetting solution, generating a fluid test sample; and quantifying the antineoplastic drug in the fluid test sample by lateral flow assay to produce an assay result, thereby detecting antineoplastic drug contamination of the surface.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: September 22, 2020
    Assignee: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION
    Inventors: Jerome Smith, Deborah Sammons, Shirley Robertson
  • Publication number: 20200230227
    Abstract: The present invention relates to a recombinant antigen derived from Zika virus E protein and use thereof. Specifically, the present invention provides a polynucleotide encoding Zika virus E protein domain III alone or repeatedly three times, a recombinant plasmid vector comprising the polynucleotide, and a DNA vaccine composition that may induce an immune response to Zika virus by expressing a Zika virus antigen protein effectively. In addition, the present invention provides a neutralizing antibody against Zika virus obtained using the polynucleotide and a method for preparing the neutralizing antibody.
    Type: Application
    Filed: December 10, 2019
    Publication date: July 23, 2020
    Applicant: Korea Center For Disease Control And Prevention
    Inventors: You-Jin Kim, Hyun Ju In, HeeJi Lim, Sun-Dong Jang, Jung-Sik Yoo, Gyung Tae Chung
  • Patent number: 10695414
    Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: June 30, 2020
    Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, Center for Disease Control and Prevention
    Inventors: Olen M. Kew, Cara Carthel Burns, Jing Shaw, Raymond Campagnoli, Jacqueline Quay
  • Patent number: 10251948
    Abstract: Provided are antigenic polypeptides of HIV envelope glycoproteins which are constructed based on amino acid mutation of attenuated live vaccine of Equine Infectious Anemia Virus, DNA constructions and recombinant virus vectors comprising polynucleotides encoding said polypeptides, antibodies against said polypeptides as well as uses thereof in preventing and treating HIV infection. Said antigenic polypeptides and vaccines can induce high titer neutralization antibodies against HIV in organism.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: April 9, 2019
    Assignee: National Center for AIDS/STD Control And Prevention, Chinese Center for Disease Control and Prevention
    Inventors: Yiming Shao, Lianxing Liu, Rongxian Shen
  • Patent number: 10064933
    Abstract: Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: September 4, 2018
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek
  • Patent number: 10036076
    Abstract: Methods of detecting influenza, including differentiating between type and subtype are disclosed, for example to detect, type, and/or subtype an influenza infection. A sample suspected of containing a nucleic acid of an influenza virus, is screened for the presence or absence of that nucleic acid. The presence of the influenza virus nucleic acid indicates the presence of influenza virus. Determining whether the influenza virus nucleic acid is present in the sample can be accomplished by detecting hybridization between an influenza specific probe, influenza type specific probe, and/or subtype specific probe and an influenza nucleic acid. Probes and primers for the detection, typing and/or subtyping of influenza virus are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: July 31, 2018
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Center for Disease Control and Prevention
    Inventors: Stephen Lindstrom, Lamorris Loftin
  • Patent number: 9913892
    Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: March 13, 2018
    Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., CORNELL RESEARCH FOUNDATION, INC., THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION
    Inventors: Patti Cynthia Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox, William L. Castleman
  • Patent number: 9879281
    Abstract: Disclosed herein is a novel recombinant virus vector derived from the attenuated vaccinia virus strain KVAC103. The recombinant virus vector is obtained by inserting an exogenous gene into the KVAC103 and may be used as a safe vaccine delivery vehicle in mammals. Particularly, recombinant viruses obtained by rescuing some of the genes deleted from the parent virus have an enhanced ability to proliferate in cells being cultured, and thus are easily produced. In addition, the recombinant viruses express an increased level of an exogenous antigen, and thus has enhanced immunogenic efficacy. Such recombinant virus vectors may be used in vaccines for preventing diseases, therapeutic vaccines, and molecular biological studies.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: January 30, 2018
    Assignee: KOREA CENTERS FOR DISEASE CONTROL AND PREVENTION
    Inventors: Ho Sun Son, Sang Gu Yeo, Sang Won Lee
  • Patent number: 9879317
    Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase, protease, or integrase of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS: 1-89, 96-122, and 124-141. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, 96-122, and 124-141. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV simultaneously or sequentially. Mutations in the reverse transcriptase, protease, or integrase of HIV can be detected using the methods described herein.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: January 30, 2018
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION
    Inventors: Jeffrey A. Johnson, Walid M. Heneine, Jonathan T. Lipscomb
  • Patent number: 9879232
    Abstract: The attenuated vaccinia virus strain KVAC103 was obtained by subculturing a vaccinia virus strain 103 times in VERO cells. The attenuated vaccinia virus strain KVAC103 has significantly low toxicity, shows reduced skin lesions, and, at the same time, induces effectively immune responses to poxvirus. Thus, it can be used as a poxvirus vaccine while causing less side effects.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: January 30, 2018
    Assignee: KOREA CENTERS FOR DISEASE CONTROL AND PREVENTION
    Inventors: Sang Gu Yeo, Ho Sun Son, June Woo Lee, Seung Bin Cha, Sun Hwa Lee, Kwi Sung Park, Sang Won Lee
  • Patent number: 9650422
    Abstract: Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glycoprotein cross-reactive epitopes and flavivirus E-glycoprotein cross-reactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: May 16, 2017
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Gwong-Jen J. Chang, Wayne D. Crill
  • Patent number: 9487832
    Abstract: A process for detecting Neisseria meningitidis nucleic acid in a sample is provided including producing an amplification product by amplifying Neisseria meningitidis nucleotide sequence of the sodC gene or mRNA using a forward primer of SEQ ID NO: 1, and a reverse primer of SEQ ID NO: 2, and detecting the amplification product to detect Neisseria meningitidis in the sample. Also provided are reagents and methods for detecting and distinguishing Neisseria meningitidis from other infectious agents. A kit is provided for detecting and quantifying Neisseria meningitidis in a sample.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: November 8, 2016
    Assignee: The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventor: Jennifer Thomas
  • Patent number: 9439935
    Abstract: Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: September 13, 2016
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek